Keck School Faculty

Sarmad Sadeghi, MD, PhD
Sarmad Sadeghi, MD, PhD
Assistant Professor of Clinical Medicine
NOR 3453 Health Sciences Campus Los Angeles
Dr. Sadeghi earned his medical degree from Tehran University. He then earned his Master's in Health Information Sciences from University of Texas, followed by a residency in general surgery and internal medicine. Dr. Sadeghi received his PhD in Public Health, immediately followed by a Hematology/Oncology Fellowship at Taussig Cancer Institute.

Dr. Sadeghi currently serves as the USC IRB Vice Chair, and as a California Cancer Consortium Distinguished Faculty Member. He also has a patent for Automated Medical Decision Making Utilizing Bayesian Network Domain Modeling.

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providersUrol Oncol. 2017 07; 35(7):459. e15-459. e24. . View in PubMed

Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have? Eur Urol Focus. 2019 Nov 18.. View in PubMed

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Cancer. 2019 Nov 01; 125(21):3853-3863. . View in PubMed

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653) J Clin Oncol. 2019 Oct 10; 37(29):2682-2688. . View in PubMed

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed

Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer Urol Oncol. 2019 01; 37(1):1-11. . View in PubMed

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. . View in PubMed

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. . View in PubMed

Comparative effectiveness of screening strategies for colorectal cancer Cancer. 2017 05 01; 123(9):1516-1527. . View in PubMed

Comparative effectiveness of screening strategies for Lynch syndrome J Natl Cancer Inst. 2015 Apr; 107(4). . View in PubMed

Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. . View in PubMed

Tivozanib in the treatment of renal cell carcinoma Biologics. 2013; 7:139-48. . View in PubMed

Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder Semin Oncol. 2012 Oct; 39(5):608-14. . View in PubMed

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome Cancer. 2012 Jul 01; 118(13):3277-82. . View in PubMed

Screening for Lynch syndrome in the general population-letter Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. . View in PubMed

A Bayesian model for triage decision support Int J Med Inform. 2006 May; 75(5):403-11. . View in PubMed

Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS Stud Health Technol Inform. 2005; 116:223-8. . View in PubMed

Determinants of operative mortality following primary coronary artery bypass surgery Eur J Cardiothorac Surg. 2002 Feb; 21(2):187-92. . View in PubMed

Self-administered decision support tool for triage: results of a retrospective study Stud Health Technol Inform. 2002; 85:45-51. . View in PubMed

Powered by SC CTSI
Go to Top